argenx SE (EBR: ARGX)
Belgium
· Delayed Price · Currency is EUR
561.40
+7.80 (1.41%)
Nov 21, 2024, 4:58 PM CET
argenx SE Revenue
argenx SE had revenue of $588.88M USD in the quarter ending September 30, 2024, with 73.28% growth. This brings the company's revenue in the last twelve months to $1.91B, up 85.56% year-over-year. In the year 2023, argenx SE had annual revenue of $1.27B with 187.66% growth.
Revenue (ttm)
$1.91B
Revenue Growth
+85.56%
P/S Ratio
19.25
Revenue / Employee
$1.66M
Employees
1,148
Market Cap
33.42B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.27B | 827.59M | 187.66% |
Dec 31, 2022 | 441.01M | -87.26M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | 92.81M | 63.58M | 217.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definitionargenx SE News
- 1 day ago - argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewsWire
- 2 days ago - Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics - Business Wire
- 7 days ago - (ARGX) - Analyzing argenx's Short Interest - Benzinga
- 8 days ago - This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
- 9 days ago - Argenx upgraded at Wolfe on myasthenia gravis dominance - Seeking Alpha
- 10 days ago - argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China - GlobeNewsWire
- 10 days ago - Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Business Wire
- 14 days ago - Peering Into argenx's Recent Short Interest - Benzinga